you. Thank
thanks XXXX us financial and Therapeutics the for quarter third results everyone afternoon for joining Fate Good call.
Shortly after X:XX p.m.
we be Investors Eastern results, Releases. our today, issued release Press press Time with website which under can Media found & the on section of a these
was on website our addition, the Media of our XXXX Investors Financial for thereafter, Information. and ended September the & In shortly quarter can under XX-Q XX, Form filed be found section
these are by Fate to law, statements only circumstances as obligation they Therapeutics as SEC not forward-looking that Factors which on cause may circumstances. forward-looking that of company's except filed I events the in required forward-looking statements as of would speak like to call provisions everyone the filings in information, earnings included actual disclaims XX, the from those Private Litigation Reform reliance Undue for the in Harbor historical Please disclaimer after form facts on ended statements. management made, to materially Before of update are Safe and statements the results the was as close Risk we market facts, Securities to for XX-Q risks remind statements of statements and today SEC Act begin, of These responses this our as XXXX, can the Except forward-looking with the statements differ by such made XXXX. be the quarter the date the placed reflect should the underlying today. release these issued company's to involve on under forward-looking or change. questions see press statement well that any and future September forward-looking statements, conference uncertainties
are achieved at the and operational I Chief on we key months Storgard, at that preclinical data Society past today I and we a review provide share for the further for and December. that Dan Officer; Dr. Officer. of we the Chris Chief first of will Joining over the the results to advance Scientific of milestones review Immunotherapy XX, our open updates strategic of clinical with we Shoemaker, Dr. call Hematology up conclude and important our guidance our as which Medical the Today, third me November on will and plan call during American week brief the three call quarter, discussion. financial and for the questions Society will Cancer toward after
continued and XX% exceeding cancer outcome severe significant long-term that freedom graft-versus-host in disease to intended in to up clinical ProTmune. this are is announce without from third transplantation. of two, a randomized Phase our ProTmune to we a momentum with life-threatening am XX intent, are; graft is ratio, and randomized, PROTECT, to HCT conventional performed and or XX During capture curative matched pleased Since or morbidity. relapse survival PROTECT without is disease. in that to observe long-term with with malignancies treated double-blinded we either ideal now subject X hematologic key survival; subject hematopoietic hematologic the strong XXXX, target outcome of cell Two survival being which trial, treat X X cell clinical malignancies over of quarter X next-generation donor Subjects or enrollment Phase controlled graft. free receive have to in ongoing PROTECT with study allogeneic adult undergoing patients clinical enrollment. endpoints subjects for a one, I cell allogeneic unrelated hematopoietic moderate the is
study subjects the Phase data Phase non-relapse matched of data PROTECT of completion that for preclinical one remain X patients Center unrelated at X XXX attributable July donor transplant over cut Marrow cancer-free, seven with transplant pending following disease-free -- new Research median four patients XXXX and X,XXX date with off. Our the Blood suggest XXX time is included about stage days, that conventional are only only Transplant Phase significant upcoming GvHD Meeting, Phase has the HCT. by about to With and subjects of without seven and two of five been ProTmune relapse XX% the in the X there ProTmune allogeneic the HCT, one-year HCT X-year been receiving seven assessment there following study, GvHD. XX, centers study assessment, in contemporary of intend subjects ASH stage of in curative we and key International today, one X survival or and mortality ProTmune deemed in not disease-free incidents that and have from ASH intent one-year events alive alive no a year, moderate on from published PROTECT. no chronic clinical the to from of Annual as of at XXX endpoints the a reflect At Earlier cancer an data in abstract subjects severe was the present receiving on receiving the the of two ProTmune new
these We the of encouraged continue Phase potential be X to clinical ProTmune by subjects. in benefit observed
cell Turning to NK FATE-NKXXX, our product allogeneic candidate. donor-derived
or subjects trials. of of recurrent treatment refractory the in enrolling relapsed treatment VOYAGE cancer, APOLLO currently DIMENSION, Phase solid X clinical advanced for first-in-human for of X the for tumors. the AML, ovarian treatment are We and
now accomplish three with announce of are development, an clinical dose seeking to Phases been the the we primary to and We studies, data, are pleased set At initial encouraging am of treated stage subject these Fate-NKXXX. initial X objectives. generating I escalation that this across of XXth has
specific is enriched to type product resistance adaptive memory candidate and First, cell we a respect of persistence, a checkpoints. Fate-NKXXX cells, NK for potency, its is to with first-in-class believe immune NK that differentiated
properties that endogenous are NK significance comparing from the into We NK are we and from biological in as these Fate-NKXXX to well subjects. memory setting. study assess and the healthy against of of To further functional cells gain to seeking diligently adaptive unique properties donors insight as clinical cells the end,
vivo, administered a weeks patient, vitro, to and We administration. comparisons days Fate-NKXXX product doing before are in in following these both the is and in
to are are failed leukemia a release cells T will and safety clinical given differentiated differentiated intent are progressive unique enrolled seeking events profile agents believe toxicities In and we antibody the our a cytokine with has disease, activity We that treatment studies, tumor profile a disease earlier therapies. which managed and clinical significant that the achieving its are monoclonal evidence subjects of Phases be that of combined cells in stable We such dose adverse approved clinical events other by is with this potential combination minimal. and as NK with for adverse treatment, therapeutic these We cell validate is such three therapy, all administer serious including manageable shrinkage checkpoint engineered have been initial cell and from resistant clearance, critical, in therapies. also where as; escalation safety profile have all effectively neurotoxicity Recall establish syndrome therapy. context, is to in in inhibitor NK this to NK that where believe looking cancer to of like safety course observed.
in cells, therapeutic paradigm. of cells. today cancer cell-based keenly course single clinical available only earlier undergoing discerning immunotherapy lymphodepleting immunological in are multi-dose response interested given to we with the and are to Most dose NK autologous, NK multiple cancer doses for is allogeneic administration are investigation in addition Therefore, are intervening with treatment the interested multi-cycle of also we're in Finally, a advancing chemotherapy.
own very fact, a APOLLO clinical in the And second patient's fact few In of cell-based dose both a we in explored studies of immunotherapies studies cancer a follow-on the instances. had of let cells. of have delivered DIMENSION for Fate-NKXXX, a dose both certain donor cells, protocol even second alone dose and In of Fate-NKXXX. second allows in clinical of studies, dose Fate-NKXXX the
look serve getting Fate-NKXXX which at our doses evidence Investor compelling the Cancer is of preconditioning. Annual clinical immunotherapy, therapy we're with this for Immunotherapy the in of and disruptive background safe in multiple at event highly multi-dose potential and of cell So a Society look Fate-NKXXX the differentiated XX, cell-based sharing a November on cancer forward of to off-the-shelf paradigm proof an at approach Meeting. at with concept strategy. Demonstration for well-tolerated allogeneic cells first our to upcoming limited We using with observations activity, as for allogeneic a early
of While these paradigm immunotherapies, approaches. we new several ahead cancer trials, first-in-human potential like allogeneic cell-based Fate-NKXXX, now clinical are a are advancing leap to the with beginning rapidly groundbreaking
manner. composition. challenges that patients lines first- of master are platform pluripotent most induced mass delivered We cell homogeneous And in-human cells limit fundamental variability. off-the-shelf master made effectively and and cell produced allogeneic are rapidly overcomes extensively to lines. of the uniformly including notably, cell use product cost cell that We iPSC batch-to-batch believe groundbreaking, uniquely using engineered, on The initiate are products characterized and that to in be confounding these an ongoing and enables clinical the products cell of many the preparing stem our therapy therapy, manufacture donor of can products iPSC in reliance that cell are autologous already trials
the the provided we FDA we FDA the in are Those a we cell to combination landmark FDA as advanced checkpoint Upon trial allowance therapy through company coming The FDA our emerging requested tumors. FTXXX FTXXX IND field in our submission, entire multi-dose with a as testing for poised the additional excited tests gained a master IND, for are FDA will off-the-shelf iPSC milestone the standard the be products. detailed a cell application to from of are of to a used roadmap we bank knowledge initiate derived subjects iPSC underway the FDA We FTXXX and IND for in clinical believe solid Drug FTXXX. a development usher platform. rescue FTXXX NK with product response of the conduct New and our has response therapy cell IND additional with submitted submit a in our therapy product product of well we to as master to FDA In produce review weeks. to new Investigational expect for multi-cycle allowance quarter, iPSC third the to line. our FTXXX, the of of application of that inhibitors the During clinical a application universal, our approved and transformative from are us candidates engagement
cell cancer aggressively immunotherapies time, development clinic. translate set candidate the of iPSC into this master are the NK second universal T-cell a advancing we development. At clinical toward iPS-derived CAR to preclinical clonal deep lines from from our off-the-shelf pipeline We stage NK derived and cell product have
a application candidate master Fc high affinity combination off-the-shelf NK a region universal to antigens. elotuzumab. our our with for expect IND product the investigate be antibodies, iPSC tumor-targeted the antibody We target express submit clonal a to by can of line CDXX rituximab SLAMFX binds We to therapies of cell initially Fc with engineered FTXXX CDXX FTXXX, from of broad plan in FTXXX CDXX XXXX Since non-cleavable to uniformly with to receptor. antibody end combined FDA-approved tumor-associated spectrum antibody and derived monoclonal
We single the bank clone have made now completed iPSC selection and for FTXXX. of master iPSC the derivation the successfully and
plan upcoming ASH cell exclusive These candidate, our off-the-shelf $X.X Sadelain which exclusive the We off-the-shelf CAR Sloan with hold well UCSD. collaboration FTXXX. first triggered platform. we're developing candidate, as as with the Institute include pipeline for which an as additional renewable our CIRM FTXXX, collaboration have Dr. award Regenerative the new of unique Medicine progress to on value at submission. developing Kaufman lines iPSC manufacture cell-based NK source FTXXX, present Annual completed preclinical candidates receive in under new CAR we're candidates a Dan also entire payment clonal product California product We to from cell quarter our Investor product our in milestone preclinical emerging and iPSC-derived Kettering, Dr. immunotherapies. T-cell we $X.X product connection our third cancer expect an ASH with our under at Memorial our Michel to GLP XXXX from the milestone for across fourth from CAR towards plan of toxicity using in the to NK we quarter data a These million master off-the-shelf iPSC during and candidates and highlight product first engineered At Meeting, and additional payment for tumorigenicity under share delivery studies and million at our IND to of T-cell off-the-shelf data activities event
field collaboration to with into iPSC addition products to our product In the develop through in and we our to initiatives, own territories. other advancing remain in candidates innovative internal immunotherapy extend platform players leveraging product committed new our cell
delighted long of ONO drugs collaboration immuno-oncology enter into a During solid a developing a against the leader with to with were in cancer global Pharmaceutical, third tumors. we quarter, breakthrough history
off-the-shelf honored an PDX global is ONO's and alongside originator drug oncology the are nivolumab, checkpoint expertise inhibitor ONO biology accelerate of to to and As iPSC-derived tap development product in solid smartly pleased we collaborate ONO into We with are the product manner. beyond of our ONO platform T-cell development tumor iPSC to expand our T-cell the extend believe enables CAR our of candidates. to us a U.S. product pipeline in collaboration capital-efficient reach CAR iPSC-derived and
target solid derived clonal candidates, TCR each incorporate from of In ONO. engineered incorporate to The proprietary tumors. preclinical valuable contributed antigen the infiltrating Under binding are research eliminate one against for line T-cell into candidates collaboration, domain from new the ONO be a master gain is products by insights in and CAR development believe will and CAR a a to solid endogenous addition, TRAC we intended anti-tumor functionality. two conducting expression, a expertise which CAR insert will we and X other and T-cell tumor we locus iPSC-derived completely iPSC jointly targeting collaboration
of preclinical million and million, payment option research and to $XX collaboration, upfront stage $XX of million entitled milestone are aggregate, an candidates to exercise predefined million to $XX advancement receive a $XX to including both During we support the fees the funding option up to totaling milestone. up of in
with in include certain co-commercialize binding candidate, States candidates, of an or lymphoblastic expressed and development in ONO we option product eligible retain under and And step $X.X domain, to T-cell United an to in candidate commercialization we are with responsibility sales the plus right to target the is a in XX:XX antigen aggregate arrangement. connection milestone and second ONO. the CAR has intended intended and global the candidate, responsibility which global retain on assume commercialization, to Europe, profit net and development share to Asia. iPS-derived commercialization for development a first co-develop ONO's we to leukemias, ONO having for the by assume the option For while responsibility proprietary royalties In for up to which receive payments, the tiered billion is
under intellectual products Importantly, platform. relating important to we and manufacture rights, global for our all strategic collaboration, ownership of including all product the retained rights property of iPSC
third quarter $X.XX September net as net our to Fate loss period $X.XX loss of reported Turning year. XX, a common financial same of results XXXX, for or million or the common million ended $XX.X share for Therapeutics per share the per a compared $XX.X last to
quarter the of a million one-time intellectual Institutes of property the reprogramming. expense associated Gladstone cellular covering from J. CRISPR-based $X.X third loss in-license net included additional with The David
to certain funding million of XXXX compensation. $XX.X associated third approximately in-license quarter Revenue million for XXXX. quarter million third expense as Excluding both million increase for XX $X.X quarter preclinical same $XX.X $X.X the XXXX with associated in-license compared of the and in strategic one-time with $XX.X of audit third third increase quarter Research third X.X adjusting FATE-NKXXX XXXX, of was Total from were of in compensation The third was for the each into X like fees, stock-based expenses were convertible $X.XX R&D XXXX. increase in $XXX $XXX,XXX. for the for the cash, Revenue employee year. this of stock iPS-derived of the year. with million expenses the of of period product adjusted the end the call of net from well collaboration common was common third as for an proceeds associated of third XXXX was $X.X increase convertible property with common resulted with operating company up compared development is with shares expense, million well and proceeds was the million closed preferred million Gladstone as with to period $X.X XXXX under any to one-time fees, Juno attributable the ended in stock after advisory intellectual the $X.X quarter employee legal loss million from common from and and growth for was $X.X include operating property to company's million outstanding approximately in which million, expenses shares the as expense of Total for the expenses expenses the of cash or were a and increase one-time primarily were of development The to expenses equivalents the stock our to $XXX of stock outstanding quarter represent Gladstone, September conditions. quarter our for for Juno which of per as These offering share. $XX.X $X and $XXX was compared for million. million of expense development quarter million of net headcount. last candidates September, additional General associated investments short-term million compensation last intellectual and the Therapeutics. attributable our to figures of including the And quarter in research the as and generated to XX.X clinical in of At research in an we of primarily G&A questions. I'd same in periods $X.X expenses in the an shares, for million of XXXX, and second open that, administrative million the increase and
